Wu L - Search Results

1

A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.

Chen B, Yao W, Li X, Lin G, Chu Q, Liu H, Du Y, Lin J, Duan H, Wang H, Xiao Z, Sun H, Liu L, Xu L, Xu Y, Xu F, Kong Y, Pu X, Li K, Wang Q, Li J, Li B, Xia Y, Wu L. Chen B, et al. Among authors: wu l. Br J Cancer. 2024 Feb;130(3):450-456. doi: 10.1038/s41416-023-02519-0. Epub 2023 Dec 18. Br J Cancer. 2024. PMID: 38110665 Clinical Trial.

2

Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.

Zhang JT, Li Y, Yan LX, Zhu ZF, Dong XR, Chu Q, Wu L, Zhang HM, Xu CW, Lin G, Yu ZY, Hu J, Zhu B, Wang HJ, Yang F, Song ZB, Han ZB, Li MX, Lin J, Wu YL, Wang JL, Zhong WZ. Zhang JT, et al. Among authors: wu yl, wu l. Lung Cancer. 2020 Jan;139:118-123. doi: 10.1016/j.lungcan.2019.11.004. Epub 2019 Nov 11. Lung Cancer. 2020. PMID: 31775086 Free article.

3

Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort.

Song Y, Hu C, Xie Z, Wu L, Zhu Z, Rao C, Liu L, Chen Y, Liang N, Chen J, Hu C, Yang N, Hu J, Zhao W, Tong G, Dong X, Zheng D, Jin M, Chen J, Huang M, He Y, Rosell R, Lippi G, Mino-Kenudson M, Han-Zhang H, Mao X, Zhang L, Liu H, Field JK, Chuai S, Ye J, Han Y, Lu S; Written on behalf of AME Lung Cancer Collaborative Group. Song Y, et al. Among authors: wu l. Transl Lung Cancer Res. 2020 Apr;9(2):269-279. doi: 10.21037/tlcr.2020.03.17. Transl Lung Cancer Res. 2020. PMID: 32420066 Free PMC article.

4

[Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics].

Radiotherapy-Immunotherapy Discussion Group; Ai X, Cai Y, Chu Q, Han C, Lu Y, Qin S, Wu L, Xie C, Yuan Z, Zhong W, Zhu X, Chang JY, Zhu Z. Radiotherapy-Immunotherapy Discussion Group, et al. Among authors: wu l. Zhongguo Fei Ai Za Zhi. 2020 Jun 20;23(6):532-540. doi: 10.3779/j.issn.1009-3419.2020.102.24. Zhongguo Fei Ai Za Zhi. 2020. PMID: 32517461 Free PMC article. Review. Chinese.

5

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy.

Jiang M, Peng W, Pu X, Chen B, Li J, Xu F, Liu L, Xu L, Xu Y, Cao J, Wang Q, Li K, Wang J, Wu L. Jiang M, et al. Among authors: wu l. Front Oncol. 2020 Jun 30;10:913. doi: 10.3389/fonc.2020.00913. eCollection 2020. Front Oncol. 2020. PMID: 32695663 Free PMC article.

6

Silencing of long non-coding RNA SOX21-AS1 inhibits lung adenocarcinoma invasion and migration by impairing TSPAN8 via transcription factor GATA6.

Xu Y, Wu H, Wu L, Xu L, Li J, Wang Q, Pu X. Xu Y, et al. Among authors: wu h, wu l. Int J Biol Macromol. 2020 Dec 1;164:1294-1303. doi: 10.1016/j.ijbiomac.2020.07.172. Epub 2020 Jul 19. Int J Biol Macromol. 2020. PMID: 32698071

7

Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People's Republic of China.

Fu R, Wu L, Zhang C, Chu Q, Hu J, Lin G, Yang L, Li JS, Yang XN, Yang JJ, Zhou Q, Wu YL, Zhong WZ. Fu R, et al. Among authors: wu yl, wu l. JTO Clin Res Rep. 2020 Sep;1(3):100053. doi: 10.1016/j.jtocrr.2020.100053. Epub 2020 May 20. JTO Clin Res Rep. 2020. PMID: 32929416 Free PMC article.

8

Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.

Zeng J, Mao WM, Chen QX, Luo TB, Wu YL, Zhou Q, Yang XN, Yan HH, Zhong WZ, Wang Q, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT. Zeng J, et al. Among authors: wu yl, wu l. Lung Cancer. 2020 Dec;150:164-171. doi: 10.1016/j.lungcan.2020.09.027. Epub 2020 Oct 8. Lung Cancer. 2020. PMID: 33186858 Clinical Trial.

9

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).

Lu S, Wang J, Cheng Y, Mok T, Chang J, Zhang L, Feng J, Tu HY, Wu L, Zhang Y, Luft A, Zhou JY, Ma Z, Lu Y, Hu C, Shi Y, Ying K, Zhong H, Poddubskaya E, Soo RA, Chia YH, Li A, Li A, Wu YL. Lu S, et al. Among authors: wu yl, wu l. Lung Cancer. 2021 Feb;152:7-14. doi: 10.1016/j.lungcan.2020.11.013. Epub 2020 Nov 24. Lung Cancer. 2021. PMID: 33321441 Free article. Clinical Trial.

10

Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.

Peng W, Pu X, Jiang M, Wang J, Li J, Li K, Xu Y, Xu F, Chen B, Wang Q, Cao J, Chen Y, Wu L. Peng W, et al. Among authors: wu l. Lung Cancer. 2021 Feb;152:66-70. doi: 10.1016/j.lungcan.2020.12.008. Epub 2020 Dec 9. Lung Cancer. 2021. PMID: 33352385 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30,797 results

Search Page